February 27, 2018 / 4:47 PM / 8 months ago

Roche says haemophilia drug Hemlibra wins EU approval

ZURICH, Feb 27 (Reuters) - Swiss group Roche said on Tuesday the European Commission has approved its drug Hemlibra for people with haemophilia A who have developed resistance to standard treatments.

The approval was expected after a panel recommended it last month. The drug was already approved in the United States last year.

Hemlibra is among the new medicines that the Basel-based pharmaceuticals maker hopes will offset falling sales of its three biggest drugs, Rituxan, Avastin and Herceptin. Some analysts expect peak Hemlibra sales of more than $4 billion a year.

‍​ (Reporting by Silke Koltrowitz, Editing by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below